Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (31-40 of 159) with videos related to

Pageof 16
Sort By:
BMC Musculoskeletal Disorders|November 19, 2011
Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT studyBoulos Haraoui, Alfred Cividino, Jacqueline Stewart, et al.
The Journal of Rheumatology|February 16, 2022
Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis RegistryMohammad Movahedi, Angela Cesta, Xiyuing Li, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 4, 2023
The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as Demonstrated by a Systematic Review and Meta-analysisAbir Mokbel, Mohammad Movahedi, Eleni Philippopoulos, et al.
Rheumatology (Oxford, England)|December 11, 2019
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trialsEdward C Keystone, Harris A Ahmad, Yusuf Yazici, et al.
The Journal of Rheumatology|May 8, 2003
Therapeutic implications for interferon-alpha in arthritis: a pilot studyThomas Wong, Beata Majchrzak, Earl Bogoch, et al.
The Journal of Rheumatology|February 3, 2011
Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritisEdward C Keystone, Arthur Kavanaugh, Michael E Weinblatt, et al.
Arthritis Research & Therapy|March 16, 2012
TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblastsAlison M Connor, Nizar Mahomed, Rajiv Gandhi, et al.
Annals of the Rheumatic Diseases|September 12, 2012
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazineEdward C Keystone, Millie M Wang, Mark Layton, et al.
The Journal of Rheumatology|December 17, 2009
Can tumor necrosis factor inhibitors be safely used in pregnancy?Yaser M Ali, Bindee Kuriya, Catalina Orozco, et al.
Radiology|April 22, 2009
Comparison of 1.0-T extremity MR and 1.5-T conventional high-field-Strength MR in patients with rheumatoid arthritisAli M Naraghi, Lawrence M White, Chirag Patel, et al.
Pageof 16

Showing results (31-40 of 159) with videos related to

Sort By:
Pageof 16
BMC Musculoskeletal Disorders|November 19, 2011
Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT studyBoulos Haraoui, Alfred Cividino, Jacqueline Stewart, et al.
The Journal of Rheumatology|February 16, 2022
Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis RegistryMohammad Movahedi, Angela Cesta, Xiyuing Li, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 4, 2023
The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as Demonstrated by a Systematic Review and Meta-analysisAbir Mokbel, Mohammad Movahedi, Eleni Philippopoulos, et al.
Rheumatology (Oxford, England)|December 11, 2019
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trialsEdward C Keystone, Harris A Ahmad, Yusuf Yazici, et al.
The Journal of Rheumatology|May 8, 2003
Therapeutic implications for interferon-alpha in arthritis: a pilot studyThomas Wong, Beata Majchrzak, Earl Bogoch, et al.
The Journal of Rheumatology|February 3, 2011
Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritisEdward C Keystone, Arthur Kavanaugh, Michael E Weinblatt, et al.
Arthritis Research & Therapy|March 16, 2012
TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblastsAlison M Connor, Nizar Mahomed, Rajiv Gandhi, et al.
Annals of the Rheumatic Diseases|September 12, 2012
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazineEdward C Keystone, Millie M Wang, Mark Layton, et al.
The Journal of Rheumatology|December 17, 2009
Can tumor necrosis factor inhibitors be safely used in pregnancy?Yaser M Ali, Bindee Kuriya, Catalina Orozco, et al.
Radiology|April 22, 2009
Comparison of 1.0-T extremity MR and 1.5-T conventional high-field-Strength MR in patients with rheumatoid arthritisAli M Naraghi, Lawrence M White, Chirag Patel, et al.
Pageof 16